THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, January 11, 2022
Immuno-oncology researchers are developing novel techniques to trigger the body's immune systems to launch a vigorous attack on cancer cells, perhaps minimizing the damaging side effects seen with many existing molecular cancer therapies.
FREMONT, CA: New technology approaches like synthetic biology allow scientists to harness the immune system with greater precision than ever before in the fight against cancer. Thus they are on the verge of a new generation of oncology therapies that could lead to huge breakthroughs and make a significant difference in patients' lives. Thus, most organizations are pioneering innovative immuno-oncology and molecular oncology approaches that are upending cancer treatment expectations and empowering researchers to address patients' top concerns.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Molecular oncology teams are currently using chemistry in novel ways to produce medications that target molecules that are important in cancer development. Meanwhile, immuno-oncology researchers are developing novel techniques to trigger the body's immune systems to launch a vigorous attack on cancer cells, perhaps minimizing the damaging side effects seen with many existing molecular cancer therapies. This, paired with a growing toolset of technologies, has considerably hastened the development of cancer drugs. In fact, by 2024, the global cancer therapy market is predicted to rise at a rate of 12 percent per year, reaching over 250 billion dollars.
It would be transformative to offer people with cancer the option of an off-the-shelf therapy rather than designing a bespoke solution for each patient. It would address fundamental production difficulties for starters, and patients are especially vulnerable when manufacturing chains are disrupted, or shipment is delayed.
While reducing adverse effects and boosting access is critical, one will not be able to do so until they can mass-produce immune cells. Because mRNA can command the body to manufacture a variety of cancer-fighting immune cells, the mRNA-based strategy, which took a huge step forward with the discovery of COVID-19 vaccines, has the potential to bring high efficacy and enhanced safety to cancer therapy. Not only that, but mRNA is easier to manufacture and supply on a large scale than protein-based treatments: instead of going through the lengthy process of purifying antigens, manufacturers merely need the mRNA sequences. As drug companies and biotechs prepare to increase therapy choices for cancer patients dramatically, many eyes are on the 252 ongoing studies using mRNA in cancer research.
On the horizon, one can see the next wave of cancer immunotherapy. The sector is getting closer to developing novel, targeted medicines that could help patients achieve long-term remission with fewer adverse effects. It is tough to exaggerate the significance of this for patients and cancer care professionals.
More in News